Three patents currently held, every record listed here
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2028. from the record
Of the 2 now held by other companies, 1 name Amr Bio Limited as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Apr 2028
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2011 to 2038.
US 8,008,529
Chiral Ligands Used in Transition Metal Catysts for Asymmetric Addition Reactions Especially Hydrogenation
Apr 9, 2028
US 11,066,408
Crystalline Binary Sodium Salts of 5-Methyl-(6S)-TETRAHYDROFOLIC Acid with Organic Bases
Mar 28, 2038
20172023202920352038
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2028 · High confidence
Also notable
Ends Nov 2028 · High confidence
Also notable
Ends Jan 2038 · High confidence
Chiral Ligands Used in Transition Metal Catysts for Asymmetric Addition Reactions Especially Hydrogenation
US 8,008,529
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2028.
Ferrocenediphosphines
US 8,106,227
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
Production of N-Substituted Aromatic Hydroxylamine
US 11,220,484
The newest of the three, granted 2022. It anchors the portfolio to 2038, later than anything else here.
Formerly held, still cited
Notable
Ends Apr 2027 · Medium confidence
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2027.
now held by Amr Bio Limited
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 term has ended since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Production of N-Substituted Aromatic Hydroxylamine | 1 in force | to Jan 2038 |
| Ferrocenediphosphines | 1 in force | to Nov 2028 |
| Chiral Ligands Used in Transition Metal Catysts for Asymmetric Addition Reactions Especially Hydrogenation | 1 in force | to Apr 2028 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,008,529 | Chiral Ligands Used in Transition Metal Catysts for Asymmetric Addition Reactions Especially Hydrogenation In force · High confidence | In force | High confidence | |
| US 8,106,227 | Ferrocenediphosphines In force · High confidence | In force | High confidence | |
| US 11,220,484 | Production of N-Substituted Aromatic Hydroxylamine In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 2 patents in force now held by others · 28 patents ended · 15 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
4 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed